DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
The generic ingredient in XERAVA is eravacycline dihydrochloride. Additional details are available on the eravacycline dihydrochloride profile page.
Generic Entry Opportunity Date for 211109
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||POWDER;INTRAVENOUS||Strength||EQ 50MG BASE/VIAL|
|Approval Date:||Aug 27, 2018||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Aug 27, 2028|
|Regulatory Exclusivity Use:||GENERATING ANTIBIOTIC INCENTIVES NOW|
|Regulatory Exclusivity Expiration:||Aug 27, 2023|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Patent:||Start Trial||Patent Expiration:||Aug 7, 2029||Product Flag?||Substance Flag?||Delist Request?|
|Patented Use:||TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER|
Complete Access Available with Subscription